The Investor Relations Group

NIAID supports research into etiology of fungal-induced inflammation in chronic sinusitis

Researchers will identify Alternaria fungus antigens responsible for chronic sinusitis and its link to asthma. The goal is to develop new treatments and understand disease mechanisms.

SourceThe Investor Relations Group·DateJun 1, 2007

BiovaxID™ yields 89 percent survival in patients with aggressive non-Hodgkins

A Phase 2 clinical study revealed that BiovaxID, a personalized anti-cancer vaccine, induced anti-tumor T-cell responses in most patients despite B-cell depletion. The overall survival rate was 89%, showing the vaccine's potential to treat other types of non-Hodgkin's lymphoma.

SourceThe Investor Relations Group·JournalNature Medicine·DateJan 24, 2006